Isepamicin was assessed in HEK293 and MDCK cells using the MTT assay to determine nephrotoxicity. The reported result was >100 mM in each model. [1]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Isepamicin nephrotoxicity assessment in HEK293
Cell-based study · HEK293 [1]
Isepamicin was added to designated wells containing HEK293 cells, and nephrotoxicity was assessed using the MTT assay. The reported result was >100 mM.
Literature-Reported Treatment Conditions
- Exposure duration
- After 68 h of incubation, 20 μl MTT solution (4 mg/ml) was added to each well and the cells were further incubated for additional 4 h in the incubator.
- Method
- added into the designated wells
- Reported limits
- Not stated in the sentences used: dose, vehicle, control.
Methods and source locations
Compound reported in the paper: Isepamicin
Evidence for Isepamicin as the sulfate form reported in the paper, not the free base/neutral form supplied as A11662; no salt equivalence, dose conversion or lot validation.
Materials and Methods > Minimum Inhibitory Concentration Assay > Cytotoxicity Assay (S29, S31, S32); Table 2 (T2.h1, T2.h2, T2.r2)
Nephrotoxicity of the antibiotics was determined by the MTT assay: Nephrotoxicity of the antibiotics was determined by the MTT assay — Materials and Methods > Minimum Inhibitory Concentration Assay > Cytotoxicity Assay (S29); Table 2 (T2.h1, T2.h2, T2.r2)
Isepamicin nephrotoxicity assessment in MDCK
Cell-based study · MDCK [1]
Isepamicin was added to designated wells containing MDCK cells, and nephrotoxicity was assessed using the MTT assay. The reported result was >100 mM.
Literature-Reported Treatment Conditions
- Exposure duration
- After 68 h of incubation, 20 μl MTT solution (4 mg/ml) was added to each well and the cells were further incubated for additional 4 h in the incubator.
- Method
- added into the designated wells
- Reported limits
- Not stated in the sentences used: dose, vehicle, control.
Methods and source locations
Compound reported in the paper: Isepamicin
Evidence for Isepamicin as the sulfate form reported in the paper, not the free base/neutral form supplied as A11662; no salt equivalence, dose conversion or lot validation.
Materials and Methods > Minimum Inhibitory Concentration Assay > Cytotoxicity Assay (S29, S31, S32); Table 2 (T2.h1, T2.h2, T2.r2)
Nephrotoxicity of the antibiotics was determined by the MTT assay: Nephrotoxicity of the antibiotics was determined by the MTT assay — Materials and Methods > Minimum Inhibitory Concentration Assay > Cytotoxicity Assay (S29); Table 2 (T2.h1, T2.h2, T2.r2)